Natalizurnab in multiple sclerosis: the second treatment revolution

被引：0
|
作者：
Tourbah, Ayman [1 ]
机构：
[1] Hop Maison Blanche, Serv Neurol, CHU Reims, F-51092 Reims, France
来源：
PRESSE MEDICALE | 2008年 / 37卷 / 01期
关键词：
D O I：
10.1016/j.lpm.2007.10.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Notalizumob (Tysobri(R)) is the first monoclonal antibody indicated for the treatment of active relapsing-remitting multiple sclerosis. Notalizumob is reserved for hospital use. Strict monitoring is necessary to detect side effects associated with the perfusion of the product, possible inefficacy of the treatment and, more rarely infectious complications, some of which (for example, progressive multifocal leukoencephalitis) are severe. Rigorous collection of efficacy and tolerance data will make it possible to assess the impact of this treatment on the natural history of multiple sclerosis.
引用
收藏
页码：81 / 84
页数：4
相关论文
共 50 条
  • [1] The efficacy of natalizurnab monotherapy over 3 years of treatment in patients with relapsing multiple sclerosis
    O'Connor, Paul W.
    Goodman, Andrew
    Kappos, Ludwig
    Lublin, Fred
    Miller, David
    Polman, Chris
    Rudick, Richard
    Fisher, Elizabeth
    Lynn, Frances
    Panzara, Michael
    [J]. NEUROLOGY, 2007, 68 (12) : A275 - A275
  • [2] Multiple Sclerosis and the Iranian Revolution
    Pakpoor, Julia
    Ramagopalan, Sreeram V.
    [J]. NEUROEPIDEMIOLOGY, 2012, 38 (02) : 122 - 122
  • [3] MULTIPLE SCLEROSIS AND THE IRANIAN REVOLUTION
    Pakpoor, Julia
    Ramagopalan, Sreeram
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2013, 84 (11):
  • [4] IS SECOND-LINE IMMUNOMODULATORY TREATMENT EFFECTIVE IN MULTIPLE SCLEROSIS?
    Racz Lilla
    Berenyi Ervin
    Barsi Peter
    Bernath David
    Csepany Tunde
    [J]. IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2017, 70 (7-8): : 275 - 283
  • [5] Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizurnab Evidence for disease heterogeneity
    Leussink, Verena I.
    Lehmann, Helmar C.
    Hoerste, Gerd Meyer zu
    Hartung, Hans-Peter
    Stueve, Olaf
    Kieseier, Bernd C.
    [J]. JOURNAL OF NEUROLOGY, 2008, 255 (09) : 1436 - 1438
  • [6] Erratum: Multiple sclerosis—a quiet revolution
    Richard M. Ransohoff
    David A. Hafler
    Claudia F. Lucchinetti
    [J]. Nature Reviews Neurology, 2015, 11 : 246 - 246
  • [7] When should second-line treatment of multiple sclerosis be started?
    Losy, Jacek
    [J]. AKTUALNOSCI NEUROLOGICZNE, 2015, 15 (03): : 124 - 129
  • [8] Natalizurnab in multiple sclerosis -: Monitoring CD4:CD8 ratios and JC viral loads
    Lonergan, Roisin M.
    Costelloe, Lisa F.
    Fletcher, Jean M.
    De Gascun, Cillian F.
    Coughlan, Suzie
    Duggan, Marguerite S.
    Doyle, Katie
    Jordan, Sinead
    Hall, William W.
    Hutchinson, Michael W.
    Tubridy, Niall J.
    [J]. NEUROLOGY, 2008, 70 (11) : A383 - A383
  • [9] Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis
    Putzki, N.
    Kollia, K.
    Woods, S.
    Igwe, E.
    Diener, H. C.
    Limmroth, V.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (03) : 424 - 426
  • [10] Preclinical and clinical development of a second generation peptide copolymer for the treatment of multiple sclerosis
    Kovalchin, Joseph
    Krieger, Jeffrey
    Dufour, Ingrid
    Collins, Kathy
    Genova, Michelle
    Augustyniak, Michael
    Rafuse, Kristen
    Patat, Alain
    Patel, Uday
    Masciali, Edward
    Zanelli, Eric
    [J]. CLINICAL IMMUNOLOGY, 2008, 127 : S112 - S113
12345